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Abstract
Background: Relationship of hepatitis C virus (HCV) infection with an increased risk of cardiovascular disease (CVD)
in HIV-infected patients remains controversial. We evaluated endothelial function and subclinical atherosclerosis in
HIV-infected patients with and without HCV.
Methods: Flow-mediated dilatation (FMD) of the brachial artery and circulating levels of cell adhesion molecules
(CAM) were measured in HCV/HIV-coinfected and HIV-monoinfected patients. Subclinical atherosclerosis was
assessed by carotid intima-media thickness (cIMT).
Results: 63 (31%) HCV/HIV-coinfected and 138 (69%) HIV-monoinfected patients were included. Median soluble
vascular CAM-1 (sVCAM-1) and intercellular CAM-1 (sICAM-1) levels were significantly higher in HIV/HCV-coinfected
patients (P < 0.001 for both cases). Median (interquartile range) FMD was 6.21% (2.86-9.62) in HCV/HIV-coinfected
and 5.54% (2.13-9.13) in HIV-monoinfected patients (P = 0.37). Adjustment for variables associated with HCV and
FMD disclosed similar results. FMD correlated inversely with cIMT and age. Carotid IMT did not differ between
HCV/HIV-coinfected and HIV-monoinfected patients in unadjusted (0.61 [0.55-0.65] mm vs 0.60 [0.53-0.72] mm; P =
0.39) or adjusted analyses.
Conclusion: HCV infection was associated with higher levels of sICAM-1 and sVCAM-1, but no evidence of
increased subclinical atherosclerosis was found when endothelial function was evaluated through FMD, or when
assessing the cIMT.
Background
Relationship of hepatitis C virus (HCV) infection with an
increased risk of cardiovascular disease (CVD) in HIV-
infected patients remains controversial. While data from
large cohort studies support a higher frequency of cardio-
vascular events in these patients [1,2], other studies have
shown differing results [3], and no increased subclinical
atherosclerosis measured with the carotid intima-media
t h i c k n e s s( c I M T )w a sf o u n di nal a r g ec o h o r to fH C V /
HIV-coinfected compared with HIV-monoinfected
women [4].
Endothelial dysfunction (ED) is an early event in the
development of atherosclerosis [5,6]. HCV/HIV-coinfection
has been associated with ED in a study based in the
measurement of circulating cell adhesion molecules
(CAM) levels [7]. Likewise, a sustained decrease in CAM
levels (intercellular CAM-1 [ICAM-1] and vascular CAM-1
[VCAM-1]) has been described following therapy for HCV
with pegylated interferon plus ribavirin [8]. At present, the
non-invasive technique of choice to assess ED is flow-
mediated dilatation (FMD) of the brachial artery [9,10], a
validated test that has shown to be related to the preva-
lence and extent of coronary atherosclerosis [11], and to
predict future cardiovascular events [12]. To date, no stu-
dies have measured brachial FMD to assess the risk of
future CVD development in HCV-infected patients.
We aimed to evaluate ED through FMD of the bra-
chial artery and subclinical atherosclerosis through
cIMT in a cohort of HIV-infected patients with and
without HCV coinfection. * Correspondence: marmasia@ya.com
1Infectious Diseases Unit, Hospital General Universitario de Elche, Alicante,
Spain
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Setting and inclusion/exclusion criteria
The investigation was conducted at the HIV Outpatient
Clinic of the University General Hospital of Elche, Spain.
All patients visited during a four-month period (February-
June 2009) were invited to participate in this cross-
sectional study. Eligible subjects included HIV-infected
adults aged 18-75 years, whether they were coinfected with
HCV or not, and with no changes in their antiretroviral
regimen or cardiovascular risk factor therapy during the
last 6 months. Exclusion criteria were active infections,
negative HCV RNA or positive hepatitis B surface antige-
nemia in HCV-coinfected patients, HCV previous therapy
with sustained response, and pregnancy. The study was
approved by the Hospital General Universitario de Elche
Ethics Committee (CEIC), and all the patients gave their
informed consent.
Clinical and laboratory measurements
Details were taken of age, HIV-related data, cardiovascu-
lar risk factors, lipodystrophy, and hepatitis B virus coin-
fection. HCV infection was defined by a positive HCV
antibody assay and a confirmatory positive HCV RNA.
HCV genotyping (sequencing) was performed. Dyslipide-
mia, diabetes and hypertension were defined by a pre-
vious diagnosis reported by the patient and/or recorded
in the patients’ charts, or by a current prescription of
pharmacological therapy for any of such risk factors.
Patients on antiretroviral therapy and/or cardiovascular
risk factor therapy had to be on a stable treatment regi-
men for at least 6 months to be included. Lipodystrophy
was defined as the presence of body-fat changes that
could be clearly recognised by both the patient and the
doctor. The liver fibrosis scores APRI and FIB-4 were cal-
culated according to the proposed formulas (Table 1).
Blood samples were collected after an 8 hour overnight
fast for measurement of glycaemia, total cholesterol,
HDL-cholesterol, direct LDL-cholesterol, triglycerides,
creatinine, CD4 cell count and HIV plasma viral load. An
additional sample was processed by centrifugation.
Plasma aliquots obtained were stored at -80°C. All frozen
samples were subsequently defrosted, and plasma levels
of soluble vascular cell adhesion molecule-1 (sVCAM-1)
and soluble intercellular adhesion molecule-1 (sICAM-1)
were measured using commercially available ELISA kits
(Quantikine, R&D Systems Europe Ltd, UK).
Evaluation of endothelial function by flow-mediated
dilatation of the brachial artery
Endothelial function was evaluated by measuring FMD
with a high resolution linear array vascular ultrasound
transducer (Nemio XG, Toshiba Medical Systems SA) as
previously described [13]. Subjects were required to be
fasting and not use any tobacco-containing products for
8 hours before the study. Baseline vessel diameter was
determined with the mean of three measures. Then, a
forearm cuff was inflated to 240 mm Hg for 5 minutes.
Diameter of the brachial artery was measured 1 min
after cuff deflation. FMD was calculated as the ratio of
the brachial artery diameter after reactive hyperemia to
baseline diameter and was expressed as a percentage of
change. Nitroglycerin-mediated vasodilatation was also
determined. Measurements we r ep e r f o r m e db yas i n g l e
sonographist blinded to the subject’s information.
Reproducibility was assessed in 10 healthy subjects (8
men, age 44 ± 8,5 years) who were examined by the
same sonographer twice, at an interval of 2 hours. The
median (interquartile range [IQR]) intraobserver inter-
session percentage of variation for brachial artery dia-
meter was 2.38% (0-5.71), similar to previous studies
[14].
Evaluation of the carotid intima-media thickness
For determination of the carotid IMT, B-mode high reso-
lution ultrasound was used following a standard procedure
as described previously [15]. To quantify the degree of car-
otid artery wall thickening, the mean of six measures per-
formed in the posterior wall of the left and right common
carotid arteries was taken. Carotid plaques were defined as
a focal cIMT≥1 mm in any of the imaged segments.
Statistical analysis
Differences in demographic and clinical characteristics
between patients with and without HCV infection were
assessed using the chi-squared or Fisher’se x a c tt e s tf o r
categorical variables and Mann-Whitney test for continu-
ous variables. Multivariable linear regression analyses
were performed to quantify the association of HCV infec-
tion with the logarithm of FMD, CAM and cIMT after
adjustment for potential confounding factors. Potential
confounders included all variables significantly associated
with hepatitis C virus infection in univariate analysis, or
with a trend to statistical significance (P < 0.10): sex, C
CDC category, intravenous drug use, men who have sex
with men, current protease inhibitor use, lipid-lowering
therapy, smoking habit, systolic blood pressure, fasting
total cholesterol and LDL-cholesterol, APRI and FIB-4.
Additionally, to assess the effect of HCV on FMD values,
all variables associated with FMD in univariate analysis,
as well as baseline diameter of brachial artery, were also
included as potential confounders in this case: age,
hypertension, diabetes, and lipodystrophy. The same pro-
cedure was used to quantify the effect of the genotypes 1
and 4 versus 2 and 3 on FMD, CAM and cIMT. All P
values were two-tailed. It was calculated that 70 HCV/
HIV coinfected patients and 140 HIV-monoinfected
would be required to detect an absolute FMD difference
between groups of 2% (standard deviation 5%) with an
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Page 2 of 7Table 1 Characteristics of the patients with and without hepatitis C coinfection
Variable Hepatitis C virus +
(N = 63)
Hepatitis C virus -
(N = 138)
P
Age, years (median [IQR]) 43.7 (39.4-47.0) 43.5 (35.6-49.5) 0.55
Men, no. (%) 53 (84.1) 100 (72.5) 0.08
Category C of the CDC, no. (%) 13 (20.6) 49 (35.5) 0.04
IDU, no. (%) 58 (92.1) 11 (8.0) <0.001
MSM, no. (%) 0 56 (40.6) <0.001
Viral load < 50 copies/mL, no. (%) 44 (69.8) 90 (65.2) 0.63
CD4 cell count, cells/μL (median [IQR]) 530 (280-750) 495 (317.5-652.5) 0.86
On antiretroviral therapy, no. (%) 56 (88.9) 115 (83.3) 0.39
Duration of antiretroviral therapy exposure, years (median [IQR]) 9.0 (3.75-10.0) 6.0 (1.88-10.0) 0.25
Non nucleoside analog-based regimen, no. (%) 17 (27.0) 53 (38.7) 0.11
Protease inhibitor-based regimen, no. (%) 36 (57.1) 58 (42.3) 0.07
Lipodystrophy
1, no. (%) 19 (30.2) 47 (34.1) 0.63
Current smoker, no. (%) 53 (84.1) 71 (51.4) <0.001
Dyslipidemia, no. (%) 12 (19) 56 (40.6) 0.002
Lipid-lowering therapy 5 (7.9) 42 (30.4) <0.001
Hypertension, no. (%) 8 (12.7) 29 (21.0) 0.17
Diabetes, no. (%) 3 (4.8) 14 (10.1) 0.28
Pre-existing cardiovascular disease, no. (%) 2 (3.2) 3 (2.2) 0.65
Body mass index, Kg/m2 (median [IQR]) 24.05 (21.56-27.86) 25.0 (21.99-28.32) 0.48
Hepatitis B virus, no. (%) 0 4 (3.0) 0.30
Hepatitis C viral load, copies/mL (median [IQR]) 748,056 (145,564-3,204,245) - -
APRI index (median [IQR]) 0.67 (0.39-1.29) 0.22 (0.18-0.31) <0.001
Genotypes 1 and 4 (n = 37) 0.67 (0.40-1.11)
Genotypes 2 and 3 (n = 24) 0.73 (0.38-1.62) 0.93
3
FIB-4 index (median [IQR]) 1.40 (0.98-3.27) 0.91 (0.66-1.17) <0.001
Genotypes 1 and 4 (n = 37) 1.52 (1.09-2.74)
Genotypes 2 and 3 (n = 24) 1.42 (0.91-4.14) 0.86
3
Waist-to-hip ratio (median [IQR]) 0.94 (0.89-0.98) 0.93 (0.88-0.98) 0.72
Metabolic syndrome
2, no. (%) 14 (22.2) 42 (30.4) 0.31
Framingham risk at 10 years
4, % (median [IQR]) 5 (2-8) 4 (1-10) 0.69
Systolic blood pressure, mm Hg (median [IQR]) 122 (114-133) 130 (118.5-142) 0.006
Diastolic blood pressure, mm Hg (median [IQR]) 76 (69-83) 79 (71-85) 0.21
Fasting total cholesterol, mg/dL (median [IQR]) 163 (146-186) 185 (158.8-213.3) 0.001
Fasting LDL-cholesterol, mg/dL (median [IQR]) 104 (86-123) 119.5 (100-140) 0.001
Fasting HDL-cholesterol, mg/dL (median [IQR]) 41.2 (34.5-50.2) 43.5 (36.9-51.2) 0.56
Fasting triglycerides, mg/dL (median [IQR]) 131 (86-171) 137.5 (94.8-197.5) 0.30
Fasting glucose, mg/dL (median [IQR]) 87.0 (81-99) 87.0 (80.8-97) 0.93
VCAM-1, hg/mL (median [IQR]) 931.4 (707.8-1606.5) 766.6 (630.3-974.5) <0.001
ICAM-1, hg/mL (median [IQR]) 492.6 (354.4-713.1) 314.3 (251.9-408.3) <0.001
Baseline brachial artery diameter, cm (median [IQR]) 4.30 (3.87-4.53) 4.14 (3.60-4.60) 0.20
Brachial artery FMD, % (median [IQR]) 6.21 (2.86-9.62) 5.54 (2.13-9.13) 0.37
Genotypes 1 and 4 (n = 37) 6.78 (2.01-11.80)
Genotypes 2 and 3 (n = 24) 5.09 (3.02-8.29) 0.32
3
Brachial artery nitroglycerine MD, % (median [IQR]) 18.35 (15.27-25.65) 19.68 (12.31-24.57) 0.86
Genotypes 1 and 4 (n = 37) 19.44 (15.50-28.16)
Genotypes 2 and 3 (n = 24) 18.22 (11.62-22.08) 0.16
3
Carotid IMT, mm (median [IQR]) 0.61 (0.55-0.65) 0.60 (0.53-0.72) 0.39
Genotypes 1 and 4 (n = 37) 0.59 (0.52-0.65)
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Page 3 of 786% statistical power, alpha 0.05. The final statistical
power of this study including 63 and 138 patients in each
group was 83.8%.
Results
Two hundred and fourteen patients were initially
included. Of 76 patients with a positive HCV antibody
assay, 5 patients were excluded because of negative HCV
RNA, 5 patients because of previous therapy for HCV
and a negative HCV viral load, and 3 patients due to
HCV infection with positive HBV antigenemia, leaving
63 (31%) patients with HCV/HIV coinfection and 138
(69%) HIV-monoinfected patients. Characteristics of the
patients are listed in Table 1. Patients with HCV/HIV
coinfection were more frequently intravenous drug users,
were less likely to belong to the C CDC category, and
tended to receive more frequently protease inhibitors and
to be men. Among traditional cardiovascular risk factors,
patients with HCV/HIV coinfection were more fre-
quently smokers, and had a lower prevalence of dyslipi-
demia, lipid-lowering therapy, lower systolic blood
pressure, lower total cholesterol, and LDL-cholesterol.
Median sVCAM-1 and sICAM-1 levels were signifi-
cantly higher in HIV/HCV-coinfected than in HIV-mono-
infected patients (P < 0.001 for both cases, Table 1). When
adjustment was performed for the variables associated
with HCV (see Table 2), sICAM-1 levels were still 62.4%
higher in HIV/HCV coinfected patients (P < 0.001), and
sVCAM-1 tended to be higher (33.1%, P = 0.08) (Table 2).
sICAM-1 continued to be higher in HCV-coinfected indi-
viduals when only those with an HIV viral load < 50
copies/ml were selected (Table 2). There was a high corre-
lation of sICAM-1 and sVCAM-1 with APRI (Spearman’s
rho = 0.42 and 0.45 respectively) and FIB-4 Spearman’s
rho = 0.34 and 0.39 respectively) fibrosis indexes (P <
0.001 in all cases). HCV viral load correlated with
sVCAM-1 (Spearman’s rho 0.36, P = 0.008), and to a lesser
extent with sICAM-1 (Spearman’s rho 0.25, P = 0.07). No
differences between genotypes were found for sVCAM-1
or sICAM-1 in unadjusted analyses, nor after adjustment
for variables associated with HCV (P = 0.66 and P = 0.46
respectively).
Median (IQR) FMD was 6.21% (2.86-9.62)% in patients
HCV/HIV-coinfected and 5.54% (2.13-9.13)% in HIV-
monoinfected patients (P = 0.37). No correlation was
found between FMD and APRI or FIB-4 indexes. Factors
associated with a lower FMD in univariate analysis were
male sex (P = 0.001), dyslipidemia (P = 0.003), hyperten-
sion (P = 0.02), diabetes (P = 0.02), and lipodystrophy (P =
0.009). FMD correlated inversely with the cIMT (Spear-
man’s rho = -0.32; P < 0.001) and with age (Spearman’s
rho = -0.23; P = 0.001).
Table 2 shows the effect of HCV coinfection on FMD
values. After adjustment for the variables associated with
HCV and with FMD (Table 2) and for baseline artery dia-
meter, FMD remained not statistically different when
patients HCV/HIV-coinfected and HIV-monoinfected
were compared (17.23% higher FMD values in HCV/
HIV-coinfected patients, P = 0.53). To avoid the effect of
HIV viremia on the endothelial function, the same ana-
lyses were performed only in patients with undetectable
viral load (< 50 copies/ml) (Table 2). FMD was again not
different according to HCV status.
The influence of HCV genotype on FMD was also
explored. FMD values did not differ between patients
with genotypes 1/4 and 2/3 (P = 0.32). Adjusted analysis
generated similar results (P = 0.49).
Carotid IMT did not differ between HCV/HIV-coin-
fected and HIV-monoinfected patients (0.61 [0.55-0.65]
mm vs 0.60 [0.53-0.72] mm; P = 0.39). After adjustment for
the variables associated with HCV, the difference between
the two groups remained non-significant (Table 2). Analy-
sis by genotypes yielded similar results, with no significant
changes after adjustment (data not shown).
Discussion
We found that there was little difference in brachial FMD
between HCV/HIV-coinfected and HIV-monoinfected
Table 1 Characteristics of the patients with and without hepatitis C coinfection (Continued)
Genotypes 2 and 3 (n = 24) 0.63 (0.55-0.68) 0.15
3
Carotid plaques, no. (%) 25 (39.7) 48 (38.4) 0.53
All continuous variables are expressed as median (interquartile range). Categorical variables represent number (%).
IDU, intravenous drug users; MSM, men who have sex with men; FMD, flow-mediated dilatation; MD, mediated dilatation; IMT, intima-media thickness; IQR,
interquartile range.
APRI = [AST (U/L)/upper limit of normal (U/L)] × 100/platelets (10
9/L).
FIB-4 = Age × AST (U/L)/[platelets (10
9/L) × ALT
1/2 (U/L)]
1Lipodystrophy was defined as the presence of body-fat changes that could be clearly recognised by both the patient and the doctor.
2Metabolic syndrome was defined according to the new International Diabetes Federation criteria. by the existence of central obesity (waist circumference in
females > 80 cm and in males > 94 cm in Europeans) plus two of the following factors: raised triglycerides (> 150 mg/dl), reduced HDL cholesterol (< 50 mg/dl
in females and < 40 mg/dl in males), raised blood pressure (≥130/85 mm Hg), and raised fasting plasma glucose (> 100 mg/dl), or specific therapy for any of
such conditions.
3P for the comparison between genotypes 1 and 4 with genotypes 2 and 3.
4The 10-year risk of developing myocardial infarction or coronary death was calculated for each patient with the Framingham equation.
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Page 4 of 7Table 2 Association of HIV and HIV/HCV infection with flow-mediated dilatation, carotid intima-media thickness, and circulating levels of cell adhesion
molecules
Variable Mean difference in log brachial
artery FMD, % (95% CI)
P Mean difference in log
carotid IMT, mm
(95% CI)
P Mean difference in log sICAM-1,
hg/mL (95% CI)
P Mean difference in log sVCAM-1,
hg/mL (95% CI)
P
HIV/HCV vs. HIV
Unadjusted 0.10 (-0.18-0.38) 0.47 -0.05 (-0.11-0.017) 0.15 0.36 (0.22-0.50) <
0.001
0.23 (-0.10-0.55) 0.01
Adjusted 0.17 (-0.33-0.68) 0.50
1 0.05 (-0.05-0.16) 0.27
3 0.39 (0.14-0.64) 0.002
3 0.22 (0.05-0.39) 0.17
3
HIV/HCV vs. HIV
(patients with VL <
50 c/mL)
2
Unadjusted 0.009 (-0.33-0.34) 0.96 -0.08 (-0.16-0.003) 0.06 0.33 (0.14-0.52) 0.001 0.17 (-0.06-0.40) 0.14
Adjusted 0.23 (-0.45-0.90) 0.47
1 0.014 (-0.13-0.16) 0.24
3 0.55 (0.19-0.90) 0.003
3 0.21 (-0.28-0.69) 0.25
3
1Adjusted for baseline brachial artery diameter, age, sex, C CDC category, intravenous drug use, men who have sex with men, current protease inhibitor use, lipid-lowering therapy, hypertension, diabetes, smoking,
lipodystrophy, systolic blood pressure, fasting total cholesterol and LDL-cholesterol, APRI and FIB-4.
2N = 134
3Adjusted for sex, C CDC category, intravenous drug use, men who have sex with men, current protease inhibitor use, lipid-lowering therapy, smoking, systolic blood pressure, fasting total cholesterol and LDL-
cholesterol, APRI and FIB-4.
FMD, flow-mediated dilatation; IMT, intima-media thickness; HCV, hepatitis C virus; CI, confidence interval
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7patients, despite higher circulating levels of CAM among
HCV-coinfected individuals. Another surrogate marker
of atherosclerosis such as the cIMT was also not different
between groups. Patients with HCV/HIV coinfection
from our cohort differed from the HIV-monoinfected in
the prevalence of cardiovascular risk factors. HCV-coin-
fected individuals had less frequently dyslipidemia, had
lower total and LDL-cholesterol levels, lower systolic
blood pressure, and were less likely to belong to C CDC
category, while they were more frequently smokers, and
tended to be more often men, and to receive protease
inhibitors. When all those protective and detrimental fac-
tors on cardiovascular risk were adjusted for, again not
significant differences were found in endothelial function
measured through brachial FMD or in the cIMT/plaque
frequency between HCV/HIV-coinfected and HIV-
monoinfected patients. Neither were there differences in
FMD according to HCV genotype.
Our results show a pro-atherosclerotic profile in the vas-
cular inflammation biomarkers sICAM-1 and sVCAM-1.
These molecules have also been linked to hepatocellular
injury, specifically sICAM-1 has been related to liver
inflammatory activity and hepatocellular necrosis, and
sVCAM-1 to liver fibrosis [16]. Accordingly, in our
patients sICAM-1 and sVCAM-1 correlated closely with
the liver fibrosis indexes APRI and FIB-4. In contrast, we
did not find increased subclinical atherosclerosis when ED
and cIMT were assessed in HCV-coinfected patients com-
pared to HIV-monoinfected. These results are in agree-
ment with those previously described with the cIMT in a
cohort of HCV/HIV-coinfected women in the Women’s
Interagency HIV Study [4], and suggest a complex interac-
tion among factors accounting for the risk of CVD devel-
opment in HCV-coinfected patients. Whether additional
aspects associated with HCV infection, such as a more
favourable lipid profile [17] or further protective factors
related to HCV or to IDU may counteract for the pro-
atherogenic ones or if, on the contrary, other issues such
as higher plaque instability linked with inflammation
[18,19] or the pro-coagulant state associated with HCV
[20,21] may contribute to a greater incidence of ischemic
events in the absence of an overt higher atherosclerotic
burden, merits further research.
Although currently the test of choice for ED evaluation,
FMD measurement has inherent physiological variations,
and this has to be taken into account when interpreting
our results. Another limitation of the study is the cross-
sectional design and the relatively small number of
patients included; however, the sample size was in line
with other studies evaluating FMD, a technically complex
test, and indeed the study was powered enough to show
that levels of ICAM-1 and VCAM-1 were significantly
higher in HCV/HIV-coinfected patients. Additionally,
this is the first study evaluating ED through FMD of the
brachial artery in HCV/HIV-coinfected patients, with a
representative sample of the HIV population cared for in
an outpatient clinic. The inverse correlation between
IMT and FMD supports the consistency of the
measurements.
Conclusion
In HIV-infected patients, HCV infection was associated
with higher levels of ICAM-1 and VCAM-1, but no evi-
dence of increased subclinical atherosclerosis was found
when endothelial function was evaluated through bra-
chial FMD, or when assessing the cIMT. Future prospec-
tive studies are warranted to clarify the influence of HCV
infection on atherosclerotic disease in HIV-infected
patients in order to optimize the management of these
patients.
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